Clinical management of metastatic colorectal cancer in the era of precision medicine
Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …
Delivering precision oncology to patients with cancer
With the increasing use of genomic profiling for diagnosis and therapy guidance in many
tumor types, precision oncology is rapidly resha** cancer care. However, the current …
tumor types, precision oncology is rapidly resha** cancer care. However, the current …
[HTML][HTML] Liquid biopsy for advanced NSCLC: a consensus statement from the international association for the study of lung cancer
Although precision medicine has had a mixed impact on the clinical management of patients
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
with advanced-stage cancer overall, for NSCLC, and more specifically for lung …
Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus …
Background The prognosis of patients with advanced biliary tract cancer who have
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …
progressed on gemcitabine plus cisplatin is dismal. We aimed to investigate the efficacy and …
Pharmacogenomics: driving personalized medicine
Personalized medicine tailors therapies, disease prevention, and health maintenance to the
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …
individual, with pharmacogenomics serving as a key tool to improve outcomes and prevent …
Genomics to select treatment for patients with metastatic breast cancer
Cancer progression is driven in part by genomic alterations. The genomic characterization of
cancers has shown interpatient heterogeneity regarding driver alterations, leading to the …
cancers has shown interpatient heterogeneity regarding driver alterations, leading to the …
Precision oncology in metastatic colorectal cancer—from biology to medicine
Remarkable progress has been made in the development of biomarker-driven targeted
therapies for patients with multiple cancer types, including melanoma, breast and lung …
therapies for patients with multiple cancer types, including melanoma, breast and lung …
Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma
Purpose: KRAS mutation (MT) is a major oncogenic driver in pancreatic ductal
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …
adenocarcinoma (PDAC). A small subset of PDACs harbor KRAS wild-type (WT). We aim to …
[HTML][HTML] The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
KM Kerr, F Bibeau, E Thunnissen, J Botling, A Ryška… - Lung Cancer, 2021 - Elsevier
The discovery of oncogenic driver mutations rendering non-small cell lung cancer (NSCLC)
targetable by small-molecule inhibitors, and the development of immunotherapies, have …
targetable by small-molecule inhibitors, and the development of immunotherapies, have …
Treatment landscape of metastatic pancreatic cancer
S De Dosso, AR Siebenhüner, T Winder, A Meisel… - Cancer treatment …, 2021 - Elsevier
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive form of cancer with a dismal
prognosis. The lack of symptoms in the early phase of the disease makes early diagnosis …
prognosis. The lack of symptoms in the early phase of the disease makes early diagnosis …